DCA papers and clinical trials
For almost a decade there has been a growing interest in Dichloroacetate potential to successfully get rid of cancer while causing minimal harm to healthy organs. DCA is a relatively cheap substance which cannot be patented by the pharmaceutical industry, thus it could not generate profit for private drug companies. Right now, because of this reason, Dichloroacetate isn’t receiving enough funding and attention which it deserves.
Despite that, there are plenty of ongoing and completed studies which examine the facts of DCA appliance for therapy. This site will present a handful of completed scientific investigations and will constantly update you with the most recent publications related to the subject.
Below you can find full research reports of Sodium Dichloroacetate (DCA) as an anti-cancer agent.
- DCA History
- Methods and Supplements for Preventing DCA Side Effects
- DCA Safety and Side Effects
- How DCA Works
- DCA and Cancer: Non-Hodgkin’s lymphoma cured in 4 months (Case presentation)
- Multi-modality imaging to assess metabolic response to dichloroacetate treatment in tumor models
- Crosstalk among proteome, acetylome and succinylome in colon cancer HCT116 cell treated with sodium dichloroacetate
- Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors
- Frequently Asked Questions